The bronchial mucosal concentrations of lomefloxacin were determined for specimens obtained by fiber-optic bronchoscopy and compared with simultaneous concentrations in serum. The 23 patients studied were given an oral dose of 400 mg once daily for 4 days to achieve steady-state levels. The median concentration in serum was 2.5 ,ug/ml (range, 1.0 to 5 ,ug/ml), and the median bronchial mucosal concentration was 5.0 ,ug/g (range, 0.7 to 18.6 ,Lg/g). The median percent penetration was 177% (range, 69 to 541%). The concentrations in serum and mucosa exceeded the MIC for 90% of strains of organisms causing bronchial infections but not sufficiently to recommend lomefloxacin for the routine treatment of pneumococcal infections.
The likely clinical efficacy of antibiotics may be predicted from the concentrations of the agent in the tissues and secretions which are the usual sites of infection. In the respiratory tract, antibiotic concentrations in sputum have been determined, but these can be unreliable (1, 13) . The bronchial mucosa is probably the main site of acute bacterial infection in patients with chronic bronchitis and bronchiectasis (5) and, therefore, it is reasonable to measure drug concentrations at this site. Several quinolones have been found to attain higher bronchial mucosal and lung tissue concentrations than simultaneous concentrations in serum (7, 9, 17) . The aim of this study was, therefore, to assess the concentration of a new quinolone, lomefloxacin, in human bronchial mucosa. Lomefloxacin is a fluoroquinolone with a broad spectrum of in vitro activity against clinically important gram-positive and gram-negative aerobes and anaerobes, including the majority of organisms responsible for lower respiratory tract infections, including Staphylococcus aureus (18) . Like the other quinolones, it also has activity against Legionella pneumophila and Mycoplasma pneumoniae (6) . It has a prolonged serum half-life, and it is therefore appropriately given as a once-daily dose (16) .
MATERIALS AND METHODS
A total of 23 patients (14 male and 9 female) undergoing fiber-optic bronchoscopy for diagnostic purposes were studied. The indication for bronchoscopy was focal radiological abnormality in 19 patients and hemoptysis in 4 patients. The final diagnosis was squamous cell carcinoma in seven patients, and in the remainder, no abnormality was found. Ages ranged from 40 to 65 years (mean, 57 years). Lomefloxacin was self-administered in a dose of 400 mg once daily, in the morning, for 4 days, with the final dose of lomefloxacin given on the morning of the bronchoscopy, making a total of 4 ity. The mean concentration in serum was 2.8 jig/ml (standard deviation [SD], 1.0 jig/ml) and the mean biopsy concentration was 5.8 ,ug/g (SD, 3.7 ,ug/g). The mean percentage of biopsy concentration compared with the concentration in serum was 202% (SD, 94%). The medians were 2.5 ,ug/ml (range, 1.0 to 5 ,ug/ml), 5 ,ug/ml (range, 0.7 to 18.6 jig/ml), and 177% (range, 69 to 541%), respectively. There was no significant correlation between the time since the last dose of lomefloxacin and concentrations in either serum or tissue (Fig. 1) . Table 1 shows the mean concentrations in serum and tissue and the mean percent penetration at different times. Data are also shown after excluding patients 20 and 21, and results show that these patients were responsible for the high mean percent penetration after 4 h. These two patients had chronic airflow limitation, and although the mucosa was macroscopically normal, it is possible that the tissue was inflamed. After exclusion of these two patients, the mean percent penetration was 177.5 (SD, 43%).
Patients did not report any unusual symptoms during or 1 week after treatment, and none of the hematological or biochemical parameters specified above showed any significant difference before and after treatment in any patient.
DISCUSSION
The concentration of an antibiotic at the site of infection is likely to be an important determinant of its effectiveness. The site of infection represents the area where bacteria are multiplying in sufficient numbers to produce tissue damage, either by direct action on the mucosal surface or by stimulating exuberant host defenses which themselves lead to damage (11, 15) .
In the lung, the sites of infection which have previously been investigated with regard to antibiotic penetration are sputum and bronchial secretions (10, 13, 17) , bronchial mucosa (7, 9, 10) and alveolar fluid, and macrophages (2, 4, 12) . It has been suggested (7, 9, 13) 4 ,500% penetrations [9, 17] ) than the other quinolones, but as yet there is no agreed-upon explanation for this and verification of these data should be undertaken.
The mechanisms of transport of drugs into tissues are difficult to study, but there has been much in vitro work on penetration of drugs into cells. The human cells used have been monocytes, macrophages, and polymorphonuclear leukocytes (4, 8, 14) . It Our data show that the bronchial mucosal concentrations of lomefloxacin in a population of patients representative of those most likely to receive antibiotic therapy for infections of the bronchial mucosa are in excess of the MIC for 90%o of strains of the common respiratory pathogens (Haemophilus influenzae, 0.03 ,g/ml; Moraxella catarrhalis, 0.03 ,ug/ml) (6, 18) . The MIC for 90% of strains of Streptococcus pneumoniae (1 ,ug/ml) was just exceeded in all serum samples and in all but one biopsy sample (Table 1) ; that for Pseudomonas aeruginosa (4 ,ug/ml) was not reliably exceeded. These data suggest that lomefloxacin would be effective against some common respiratory pathogens of the bronchial mucosa but that further studies in which higher doses are used are required before it can be recommended for clinical trials when pneumococcal infections are suspected. The high bronchial mucosal concentrations would favor the use of this agent in Mycoplasma and Legionella infections, since a high intracellular concentration is implied at the more peripheral sites which are involved in pneumonia.
